Retreatment with nafarelin for recurrent endometriosis symptoms: efficacy, safety, and bone mineral density
article
OA: closed
CC0
⤵ 18 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This study evaluated the efficacy, safety, and impact on bone mineral density of nafarelin retreatment in patients experiencing recurrent endometriosis symptoms.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (15)
- Administration of Nasal Nafarelin as Compared with Oral Danazol for Endometriosis via openalex
- A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone via openalex
- Nafarelin therapy in endometriosis: Long-term effects on bone mineral density via openalex
- Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain via openalex
- Reduced Bone Mass in Reproductive-Aged Women with Endometriosis* via openalex
- W2061958057 via openalex
- W2129449855 via openalex
- W2325343629 via openalex
- W2472762831 via openalex
- W2796024263 via openalex
- W4298345797 via openalex
- W1512318310 via openalex
- W1990276361 via openalex
- W2002374079 via openalex
- W2031495520 via openalex
Cited by (18)
- Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not? 2023
- GnRH agonists in the treatment of symptomatic endometriosis: a review 2022
- Measures Used to Assess Chronic Pelvic Pain in Randomized Controlled Clinical Trials: A Systematic Review 2015
- Chronic Abdominal Pain of Gynecologic Causes: Diagnosis and Treatment 2014
- Systematic review of endometriosis pain assessment: how to choose a scale? 2014
- Therapeutic Efficiency of Tibolone in a Rat Endometriosis Model 2011
- Bone Density in Adolescents Treated with a GnRH Agonist and Add-Back Therapy for Endometriosis 2007
- Chronic Pelvic Pain in Men and Women: Pathogenesis, Diagnosis, and Treatment 2004
- Optimizing Gonadotropin-Releasing Hormone Agonist Therapy in Women with Endometriosis 2004
- Chronic Pelvic Pain 2003
- Chronic Pelvic Pain 2003
- Diagnosis and management of chronic pelvic pain 2002
- Acute exacerbation of chronic maxillary sinusitis during therapy with nafarelin nasal spray 2001
- Medical management of endometriosis 2000
- Current Drug Therapy Recommendations for the Treatment of Endometriosis 1999
- Medical Treatment of Endometriosis-Associated Pain 1999
- Medical Treatment of Endometriosis 1999
- Medical Management of Pain in Recurrent Endometriosis 1999
Source provenance
- europepmc
- last seen: 2026-06-23T06:15:44.889181+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:10:52.568893+00:00
License: CC0
· commercial use OK